Literature DB >> 9053838

Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines.

O Sangfelt1, S Erickson, S Einhorn, D Grandér.   

Abstract

One prominent effect of IFNs is their cell growth inhibitory activity. The exact molecular mechanism behind this inhibition of proliferation remains to be elucidated. Possible effectors for IFN-induced growth inhibition are the recently discovered cyclin-dependent kinase inhibitors. The effect of IFN-alpha treatment on the members of the Ink4 and Cip/Kip families of Cdk inhibitors was investigated in three hematopoietic cell lines Daudi, U-266 and H9. Two of these cell lines, Daudi and U-266, respond to IFN-alpha by G1 arrest, whereas the H9 cell line is not growth arrested by IFN-alpha. We show that a p53-independent upregulation of p21 mRNA occurs following IFN-alpha treatment in all three cell lines. In Daudi and U-266 cells, the mRNA induction is accompanied by an increase in p21 protein, followed by an increased binding of p21 to Cdk2 and a subsequent decrease in Cdk2 activity, temporally coinciding with G1 arrest. In both these cell lines, there was also an increased binding of p21 to Cdk4. In contrast, p21 protein was not expressed in H9 cells, despite high levels of p21 mRNA following IFN-alpha treatment. In U-266 cells, IFN-alpha increased not only p21 but also p15 mRNA and protein levels, followed by an increased association of p15 with Cdk4. Furthermore, IFN-alpha treatment caused a four- to sixfold induction of the p16 E1beta transcript in U-266 cells. Expression levels of the other Ink4 and Cip/Kip Cdk inhibitors were not induced by IFN treatment in any of the cell lines. We conclude that IFN-alpha can act as a potent regulator of Cdk-inhibitor expression, correlating with decreased Cdk activity and cell growth inhibition. One mechanism for resistance to IFN may be loss of the ability of cells to upregulate these proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9053838     DOI: 10.1038/sj.onc.1200832

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

2.  c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition.

Authors:  J Bash; W X Zong; C Gélinas
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  Interferon-α inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling.

Authors:  Thao P Nguyen; Doug A Bazdar; Joseph C Mudd; Michael M Lederman; Clifford V Harding; Gareth A Hardy; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2015-03-17       Impact factor: 4.962

4.  Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors.

Authors:  S Jayachandra; K G Low; A E Thlick; J Yu; P D Ling; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 5.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

6.  Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.

Authors:  R Marches; R Hsueh; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 7.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

8.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05

9.  Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.

Authors:  Prerna Diwan; Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 10.  Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?

Authors:  Patrick S Moore; Yuan Chang
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.